Asset Details
Do you wish to reserve the book?
Tuberculosis following the Use of Etanercept, a Tumor Necrosis Factor Inhibitor
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Tuberculosis following the Use of Etanercept, a Tumor Necrosis Factor Inhibitor
Do you wish to request the book?
Tuberculosis following the Use of Etanercept, a Tumor Necrosis Factor Inhibitor
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Tuberculosis following the Use of Etanercept, a Tumor Necrosis Factor Inhibitor
2004
Overview
Infliximab, a tumor necrosis factor (TNF) antagonist, is associated with tuberculosis (TB), but it is unknown whether this phenomenon is true of all TNF antagonists. We reviewed 25 cases of TB due to another TNF antagonist, etanercept, that were reported to the US Food and Drug Administration (FDA) between November 1998 and March 2002. Such cases are sometimes incomplete and are subject to underreporting. Fifteen patients received other immunosuppressive medications. The median interval between the receipt of the first dose of etanercept and the diagnosis of TB was 11.5 months. Thirteen patients had extrapulmonary TB at the time of diagnosis. Diagnosis was made on the basis of culture results for 12 patients, biopsy findings for 9, and sputum staining for 4. There were 2 deaths, 1 of which was directly attributed to TB. The estimated number of TB cases reported to the FDA for each person-year of treatment with etanercept (i.e., the \"reporting rate\") among patients with rheumatoid arthritis (RA) was ∼10 cases/100,000 patient-years of exposure. Clinicians considering etanercept for patients with RA should be alert to the possibility of the occurrence of TB, sometimes with an unusual extrapulmonary presentation. It is unclear whether etanercept therapy increases the risk of TB beyond the elevated TB rates already documented for patients with RA.
Publisher
The University of Chicago Press,University of Chicago Press
Subject
/ Adult
/ Adverse Drug Reaction Reporting Systems
/ Aged
/ Antibodies, Monoclonal - adverse effects
/ Arthritis, Rheumatoid - complications
/ Arthritis, Rheumatoid - drug therapy
/ Child
/ Female
/ Humans
/ Immunoglobulin G - adverse effects
/ Immunoglobulin G - therapeutic use
/ Immunosuppressive Agents - adverse effects
/ Immunosuppressive Agents - therapeutic use
/ Male
/ Receptors, Tumor Necrosis Factor - therapeutic use
/ Risk
/ Tuberculosis - chemically induced
